Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
filgotinib
Pharma
Alfasigma's JAK inhibitor Jyseleca scores in phase 3 trial
Alfasigma has presented results from a phase 3 trial of Jyseleca, which has shown promise as a treatment for active axial spondyloarthritis.
Kevin Dunleavy
Jul 29, 2025 8:50am
Galapagos sells its Jyseleca business to Italy's Alfasigma
Oct 31, 2023 9:10am
Galapagos slashes Jyseleca sales projection, scraps submissions
Aug 4, 2023 11:12am
Galapagos' Jyseleca can't prove its worth in Crohn's disease
Feb 9, 2023 11:36am
Doctors like AbbVie's Rinvoq in IBD, but not Bristol's Zeposia
Feb 22, 2021 11:17am
Gilead guts its filgotinib plans—and CEO's rebuild along with it
Dec 16, 2020 10:54am
